Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta‐Analysis of the Control Arms of Randomized Controlled Trials
Authors:
- Gabriel Figueroa‐ParraGFGabriel Figueroa‐Parra
- María C. Cuéllar‐GutiérrezMCMaría C. Cuéllar‐Gutiérrez
- Mariana González‐TreviñoMGMariana González‐Treviño
- Alain Sanchez‐RodriguezASAlain Sanchez‐Rodriguez
- Jaime Flores‐GouyonnetJFJaime Flores‐Gouyonnet
- José A. Meade‐AguilarJMJosé A. Meade‐Aguilar
- Larry J. ProkopLPLarry J. Prokop
- María Dall'ERaMDMaría Dall'ERa
- Brad H. RovinBRBrad H. Rovin
- Frédéric HoussiauFHFrédéric Houssiau
Top Cited Papers
- 28 June 2024
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (9) , 1408-1418
Abstract
Objective: Our objective was to evaluate the effect of glucocorticoid regimens on renal response, infections, and mortality among patients with lupus nephritis (LN).Methods: We performed a systematic review and meta‐analysis of the control arms of randomized clinical trials (RCTs). We included RCTs of biopsy‐proven LN that used a protocolized regimen of glucocorticoids in combination with mycophenolic acid analogs or cyclophosphamide and reported the outcomes of complete response (CR), serious infections, and death. The starting dosage of glucocorticoids, tapering method, and administration of glucocorticoid pulses were abstracted. Meta‐analysis of proportions, meta‐regression, and subgroup meta‐analysis were performed at 6 and 12 months for all outcomes.Results: Fifty RCT arms (3,231 patients with LN) were included. The predicted rates of CR, serious infections, and death when starting on oral prednisone at 25 mg/day without pulses were 19.5% (95% confidence interval [CI] 7.3–31.5), 3.2% (95% CI 2.4–4.0), and 0.2% (95% CI 0.0–0.4), respectively. Starting on prednisone at 60 mg/day (without pulses) increased the rates to 34.6% (95% CI 16.9–52.3), 12.1% (95% CI 9.3–14.9), and 2.7% (95% CI 0.0–5.3), respectively. Adding glucocorticoid pulses increased the rates of CR and death but not serious infections. We observed a dose–response gradient between the initial glucocorticoid dosage and all the outcomes at six months after accounting for the administration of glucocorticoid pulses, underlying immunosuppressant, and baseline proteinuria.Conclusion: A higher exposure to glucocorticoids during the initial therapy of LN was associated with better renal outcomes at the cost of increased infections and death.Keywords
Funding Information
- Rheumatology Research Foundation
This publication has 61 references indexed in Scilit:
- Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population‐Based Study Over Four Decades Using the Lupus Midwest NetworkArthritis & Rheumatology, 2023
- Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus NephritisJAMA Network Open, 2022
- Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score–Matched AnalysisArthritis Care & Research, 2021
- Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety StudyArthritis & Rheumatology, 2014
- Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind StudyArthritis & Rheumatology, 2013
- Overall and Cause‐Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta‐Analysis of Observational StudiesArthritis Care & Research, 2013
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III StudyArthritis & Rheumatism, 2013
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamideArthritis & Rheumatism, 2002